If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Ebullient Evolution

Thu, 29th Oct 2009 08:23
Investment management firm Evolution Group expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions.Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.The company is responding to this increased activity by boosting the division's headcount by around 10% in the second half of the year.On the Private Client Investment Management side, profits continue to pile up, while funds under management hit a record level of £5bn at the end of September, up from £4.2bn at the end of June. Net fund inflows exceeded £100m in the third quarter.'Given the successful results to date from investments made over the last 12 months and our growing business pipeline, the group is highly confident that it can continue the momentum in profit growth into 2010 and beyond,' the company said.

Related News

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well
25 Apr 2024

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests
4 Apr 2024

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat
19 Mar 2024

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

EVG.L News

Friday broker round-up
27 Jul 2018

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year
26 Jul 2018

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug ...

Evgen concludes patient recruitment in STEM breast cancer trial
25 Jul 2018

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in met...

Wednesday broker round-up
25 Jul 2018

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment
25 Jul 2018

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic...

UK Shareholder Meetings Calendar - Next 7 Days
19 Jul 2018

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials
13 Jun 2018

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, w...

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"
11 Jun 2018

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is th...